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Broad-spectrum antibiotic combination therapy is frequently applied due to increasing resistance development of infective
pathogens. The objective of the present study was to evaluate two common empiric broad-spectrum combination therapies
consisting of either linezolid (LZD) or vancomycin (VAN) combined with meropenem (MER) against Staphylococcus aureus (S.
aureus) as the most frequent causative pathogen of severe infections. A semimechanistic pharmacokinetic-pharmacodynamic
(PK-PD) model mimicking a simplified bacterial life-cycle of S. aureus was developed upon time-kill curve data to describe the
effects of LZD, VAN, and MER alone and in dual combinations. The PK-PD model was successfully (i) evaluated with external
data from two clinical S. aureus isolates and further drug combinations and (ii) challenged to predict common clinical PK-PD
indices and breakpoints. Finally, clinical trial simulations were performed that revealed that the combination of VAN-MER
might be favorable over LZD-MER due to an unfavorable antagonistic interaction between LZD and MER.
CPT Pharmacometrics Syst. Pharmacol. (2017) 00, 00; doi:10.1002/psp4.12197; published online on 0 Month 2017.
Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE
TOPIC?
 PK-PD relationships for antibiotic monotherapy have
been intensely characterized. However, for combination
therapies, which are increasingly administered due to
suspected resistant bacteria, PK-PD characterization of
antibiotic combinations is largely unexplored, even for
frequently utilized combination regimens.
WHAT QUESTION DID THIS STUDY ADDRESS?
 The present study compared two common broad-
spectrum combination therapies (i.e., either LZD or
VAN combined with MER against S. aureus, a highly
abundant infective pathogen), in a translational PK-PD
framework.
WHAT THIS STUDY ADDS TO OUR KNOWLEDGE
 This translational PK-PD study suggests that the
combination of LZD-MER might be inferior to VAN-
MER against S. aureus. Furthermore, the study illus-
trates the usefulness of modeling and simulation techni-
ques to gain insight into joint PD of antibacterial
combination therapy.
HOW MIGHT THIS CHANGE DRUG DISCOVERY,
DEVELOPMENT, AND/OR THERAPEUTICS?
 In the future, antibacterial combination therapy most
probably will become even more important. Drug devel-
opment programs need to adapt to this forthcoming
paradigm shift by including a combined evaluation of
novel drug candidates with other antibiotics already in
preclinical drug development. The presented transla-
tional approach might help in planning prospective
head-to-head combination trials and thus selecting the
most favorable combinations for clinical evaluation.
Hence, extension of the approach to further drug clas-
ses and scenarios might be useful.
Bacterial resistance to antibiotics is rising, particularly in
the clinical setting.1 Hence, nosocomial infections often
require broad-spectrum antibacterial coverage, which is
achieved by empiric antibiotic combination therapy. These
regimens frequently include linezolid (LZD) or vancomycin
(VAN), and there is an ongoing debate as to which of these
drugs has more favorable properties in the clinical setting.2
We aimed to approach this controversy from the perspec-
tive of their use in combinatory regimens. Frequently, LZD
or VAN, both displaying sole gram-positive activity, are
combined with meropenem (MER) to ascertain gram-
negative coverage. Although resistant pathogens are often
suspected in a clinical setting, methicillin-susceptible Staph-
ylococcus aureus (MSSA) will turn out as an infective
organism in most cases as the causative pathogen.3
Clinical assessment of single and combined antibacterial
effects is challenging due to a lack of direct clinical read-
outs of the antibacterial effects. Pharmacokinetic-
pharmacodynamic (PK-PD) modeling has been proven
useful to link preclinical information to clinical information to
comprehensively assess antibacterial effects and place
them in a clinical context.4 The in vitro-based PK-PD
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models have also been shown to predict PK-PD indices
from in vivo studies,5 corroborating the translational value
of in vitro information.
The objective of the present study was to characterize
and compare antibiotic combinations of either LZD-MER or
VAN-MER in a translational framework exploiting preclinical
in vitro experiments.6 We aimed to (i) develop a semi-
mechanistic PK-PD model that predicts the individual and
combined effects of LZD, VAN, and MER by accounting for
the respective mechanisms of action, (ii) externally validate
the PK-PD model with other MSSA isolates and drug com-
binations from other drug classes, (iii) assess the transla-
tional validity of the developed model by predicting PK-PD
breakpoints and comparison to the clinical PK-PD indices,
and (iv) link the developed semimechanistic mathematical
model to published clinical population PK models to assess




The dataset for PK-PD model-building was previously pub-
lished.6 Briefly, MSSA ATCC 29213 was exposed over 24
hours to static concentrations of LZD (0.5–32 mg/L), MER
(0.015–8 mg/L), and VAN (0.06–16 mg/L) alone and in
selected combinations covering the clinically relevant con-
centration range of the drugs.7–9 Samples from more than
or equal to two independent replicates per concentration
tier were taken using a dense sampling scheme (n 8);
drug concentrations were quantified by a validated assay10
and MSSA as colony forming units (CFU)/mL.
Semimechanistic PK-PD model building
A simplified life-cycle model11 was utilized as the core of
the PD model, which consisted of two bacterial growth
states: bacteria in the growing state (“GRO”) transferred
into the replicating state (“REP”). In “REP,” bacteria repli-
cated (“doubling”) and transferred back to “GRO.” The first-
order rate-constant krep was assumed to be rate-limiting
and actual replication was assumed to be very fast (kdoub
fixed to 100 h21). Bacteria being not susceptible to antibi-
otic exposure and not replicating (“persisters”) were
assumed to be generated during replication and quantified
in a compartment with nonreplicating persisting bacteria,12
(“PER”). The differential equations initialized for “GRO” with
the bacterial concentration at t5 0 (CFU0) as initial condi-






5krep3GRO2kdoub3REP2kper3REP IC5 0 (2)
dPER
dt
5kper3REP2kdeath;per3PER IC5 0 (3)
Drug effects were implemented by sigmoidal maximum
effect models on the respective turnover rate constants in
the simplified bacterial life-cycle (i.e., maximum effect
(Emax), EC50 as the concentration stimulation 50% of Emax,
and a Hill coefficient capturing the steepness of the
concentration-effect relationships. The Emax was estimated
(relative to 1.0) only if more than one drug altered a rate







The life-cycle model structure allowed for implementing the
drug effects in various ways. Inhibition of the rate constant
krep leads to purely bacteriostatic drug effects. Inhibition of
kdoub leads to a replication-dependent drug effect with a
maximum killing rate determined by the replication rate. A
replication-independent drug effect is achieved by introduc-
ing a killing rate on “GRO” or “PER” to kill growing or per-
sisting bacteria. The drug effects of LZD, VAN, and MER
were implemented in different ways, as outlined above,
guided by their mechanism of action and model selection
criteria, as outlined below.
Potential adaptive resistance (AR) of the bacteria leading
to regrowth after initial killing was implemented by an adap-
tion submodel.13,14 The degree of adaption was assumed
to increase EC50 over time as a function of drug exposure
c(t) and a second-order time-delay rate constant s:
dARoff
dt
52s3c tð Þ3ARoff IC5 1 (5)
dARon
dt
5s3c tð Þ3ARoff IC5 0 (6)
The hypothetic amount transferred to ARon was then multi-
plied by b to account for the magnitude of the adaption
resulting in an adaption factor a, that ultimately scaled the
EC50 over time
14:
EC50 tð Þ5a tð Þ3EC50 with a tð Þ511b3ARon tð Þ (7)
Potential interactions on the adaption level (i.e., if drug A
had an influence on the adaption of the bacteria to drug B),
was explored by an inhibitory effect (Emax model) of drug A
on s of drug B and/or vice versa.
Data analysis
The “R” software program version 3.1.1 (R Core Team,
Vienna, Austria) was utilized as the analysis platform for
modeling and simulations. Differential equations were
solved using the ‘R’ package “deSolve.”15 There were
1,617 timed CFU data points available for analysis of the
model-building dataset. Experimentally determined as well
as model-predicted CFU/mL were log-transformed for
parameter estimation (‘R’ package “optim”) using ordinary
least-squares with an additive residual variability compo-
nent. As experimental variability between replicates was
small, no other variability components were required. Model
performance was investigated by visual inspection of
goodness-of-fit and visual predictive check plots (stratified
by scenario). For discrimination between nested models, a
significant difference in favor of the more complex model
was assumed if the D2-fold log-likelihood (D-2LL) estimator
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was 3.84 (a 0.05; df51). For non-nested model compari-
son, the Akaike criterion16 was used. The precision of the
parameters of the final mathematical model was assessed by
a nonparametric bootstrap analysis (n5 1,200), in which the




In order to assess if the developed PK-PDmodel was predictive
also for other MSSA strains than the reference isolate ATCC
29213 (MIC values: LZD52.0 mg/L; MER5 0.125 mg/L; and
VAN51.0 mg/L), we used time-kill curve data from two clinical
isolates of MSSA,6 MV13391 (MIC values: LZD52.0 mg/L;
MER50.125 mg/L; and VAN5 1.0 mg/L) and MV13488
(MIC values: LZD52.0 mg/L; MER5 0.0625 mg/L; and
VAN5 1.0 mg/L), which originated from tracheal secretion
and sputum, respectively. We used the developed PK-PD
model with its final parameter estimates to predict the time-
kill curves obtained with these two clinical MSSA isolates. No
parameters apart from krep, CFU0, and CFUmax were altered
for this purpose.
Cross-combination prediction with a focus on PD
interaction patterns
As the model-building dataset6 contained combinations
between bacteriostatic and bactericidal agents, we evalu-
ated if the developed PK-PD model was also able to predict
antibacterial effects of such combinations from published
time-kill curve studies, including LZD and VAN,17 erythro-
mycin and penicillin,18 and chloramphenicol and ampicil-
lin.19 In particular, we aimed to assess whether the
developed model of the present work can predict the antag-
onistic interactions, which were observed with the above-
mentioned combinations. Time-kill curve data from these
publications were digitalized using GraphClick version 3.0
(Arizona-software, Zurich/Switzerland). Due to the sparse-
ness of these published datasets, no exposure response
parameters could be estimated from the data. Hence, EC50
values of the semimechanistic PK-PD model were set to
the respective minimal inhibitory concentration (MIC) of the
antibiotics as a proxy of the drugs potency. It should be
noted that the MIC does not equal EC50, but its precise value
has less of importance when predicting pure inhibitory con-
centrations above the MIC as in the external data. Further,
CFU0, CFUmax, and krep were estimated from the respective
growth control curves. The maximum drug effects were either
a result of the growth-curve for drugs exhibiting replication-
dependent killing (i.e., VAN, penicillin, and ampicillin) or were
adapted to drugs that exhibit replication-independent killing
(i.e., LZD, erythromycin, and chloramphenicol). The persister
development rate kper was set to the final parameter estimate
of MER, also due to the lack of data.
Prediction of PK-PD indices and breakpoints
The translational predictivity of the developed semimechan-
istic mathematical PK-PD model was investigated by simu-
lating a dose fractionation study.5 Therefore, published
human population PK models of MER,20 LZD,21 and VAN22
were utilized and linked to the developed semimechanistic
PK-PD model. Covariates of the population PK models
were set to 35 years for age, 75.0 kg for total body weight,
and 120 mL/min for creatinine clearance. Plasma protein
binding was set to 2% (MER),23 32.8% (VAN),24 and 13.4%
(LZD).25 Six to 10 dose levels were empirically chosen to
cover concentrations around the MIC of MSSA and ranged
from 80–1,200 mg (LZD), 2.5–20 mg (MER), and 10–
200 mg (VAN). These doses were administered 1–12
(MER) and 1–6 times (LZD and VAN) over a simulation
period of 24 hours. CFU/mL over time were predicted with
the linked PK-PD model. A bactericidal effect was con-
cluded if bacterial counts were reduced 3 log10 CFU/mL
compared to the initial inoculum; a reduction of bacteria
ranging from 0–3 log10 CFU/mL was referred to as bacteri-
ostatic. PK-PD indices26 were calculated from the simulated
time-kill curves and included: %fT>MIC5 the percentage of
time that unbound drug concentrations exceed the MIC in a
24-hour period; fCmax/MIC5 the peak unbound drug con-
centration divided by the MIC; and fAUC/MIC5 the area
under the unbound concentration-time profile divided by the
MIC in a 24-hour period. Breakpoints for bacteriostatic and
bactericidal activity were determined according to nonlinear
regression analysis and evaluated graphically and based on
the coefficient of determination (R2).
Clinical trial simulation
To explore the antibiotic effects of LZD, MER, and VAN,
alone and in dual combinations, clinically utilized dosing
regimens were used for simulations with the linked popula-
tion PK-PD model. For simplicity, all drugs were adminis-
tered as intravenous infusions over 1 hour to mimic a
common clinical situation. The exploratory scenarios were
LZD 600 mg b.i.d.,27 MER 1,000 mg t.i.d.,23 and VAN
1,000 mg b.i.d.28 alone and in dual combinations of LZD/
MER and VAN/MER. One thousand virtual patients were
simulated and their covariates, age, body weight, and
serum creatinine were sampled from log-normal distribu-
tions with geometric mean values of 75 kg, 35 years, and
1.0 mg/dL, respectively. An SD of 10% CV was used for all
covariates. Sex and likelihood of liver cirrhosis (Child Pugh
grade C) were simulated from binomial distributions with
probabilities of 50% female and 5% liver cirrhosis. Creati-
nine clearance was subsequently calculated from those
“primary” patient covariates using the Cockcroft-Gault equa-
tion.29 The (unexplained) interindividual variability on the
population PK model and uncertainty of the parameters of
the semimechanistic PD model was considered by using
stochastic simulations30: PK parameters were sampled
from the respective log-normal distributions of each PK
parameter for each individual virtual patient. Uncertainty of
the PD model parameter estimates was considered by
sampling from the obtained variance-covariance matrix of
the final semimechanistic PK-PD model. Differences in bac-
terial susceptibility were considered by sampling MIC val-
ues from the respective EUCAST distribution (www.mic.
eucast.org) for LZD, VAN, and MER (Supplementary Fig-
ure S1). The sampled MIC values were used to scale
the active concentrations of LZD, VAN, and MER in the
semimechanistic PK-PD model (i.e., Cactive drug5Cdrug/
MICEUCAST/MICATCC29213). Time-courses of CFU/mL of the




different regimens were predicted over 24 hours and com-
pared between the different therapies.
RESULTS
Semimechanistic PK-PD model
The final semimechanistic PD model that simultaneously
described the single and combined effects of LZD, MER,
and VAN against MSSA is illustrated in Figure 1, and con-













5krep t;CFUð Þ3 12ELZDð Þ3GRO2kdoub3REP




2kdeath;PER3PER IC5 0 (10)
krep was assumed to decrease asymptotically to zero if
bacterial concentrations reached the capacity limit CFUmax.
The lag-phase to attain exponential growth, as seen in GC
in Figure 2, was estimated by a first-order delay rate con-
stant klag. Both aspects were considered as follows:







MER and VAN, as cell wall-active antibiotics, impaired
successful doubling causing loss of bacteria entering repli-
cation “REP.” MER alone fully inhibited doubling (i.e., Emax
of 100% on kdoub) at optimal concentrations up to 0.5 mg/L
and to only 67.2% at higher concentrations up to 8 mg/L
(so-called paradoxical “Eagle-effect,” cf. M4 vs. M64 in Fig-
ure 2). This paradoxical effect was implemented as an
inhibitory effect on the drug effect of MER occurring at
higher concentrations, which considerably improved the
model (DAIC52104.64). VAN alone impaired successful
doubling of the bacteria to 74.3% (cf. compare the lower
killing rate of VAN to MER at optimal concentrations; e.g.,
V16 vs. M4 in Figure 2). The concentration-effect relation-
ship of initial killing of VAN (cf. V0.5 vs. V0.75 in Figure 2)
was very steep and estimation of the Hill factor H was
imprecise; hence, H for VAN was fixed to 20, as in previous
studies.12 The joint effects of VAN and MER were imple-
mented by an empirical modified Bliss Independence term
(1-EMER)3(1-EVAN), accounting for the self-inhibitory Eagle
effect of MER and the observation that the maximum joint
effect of MER and VAN was limited to the effect of VAN (cf.
M4 vs. V4M4 in Figure 2). Both VAN and MER simulated
drug-unsusceptible persisting bacteria (quantified in “PER”)
after initial killing (cf. M2 and V4), being quantified in
“PER,” whose inclusion was highly significant for MER (D-
2LL5264.89) and VAN (D-2LL5247.8).
LZD, as a protein synthesis inhibitor, inhibited transition of
the bacteria into the replicating state “REP.” Hence, bacteria
were growth-arrested in “GRO” in the presence of LZD and
only a replication-independent killing of bacteria was
observed (kdeath,LZD; e.g., as apparent in L16 in Figure 2).
When MER was combined with LZD, growth-arrested bacte-
ria were protected from the replication-dependent effect of
MER and the combined effect corresponded to the effect of
LZD alone explaining the antagonism between LZD and
MER in a mechanistic fashion (cf. M4 vs. L4 vs. L4M4 in
Figure 2).
Both MER and VAN showed significant degradation dur-
ing the time-kill curve study to 62.9% and 90.6% of their
concentration at t5 0, respectively10: drug degradation was
considered in the PK-PD model by implementing first-order
Figure 1 Graphical sketch of the semimechanistic pharmacodynamic model (left) and adaption submodel of vancomycin (VAN) and
meropenem (MER) (right) for lag-phase Staphylococcus aureus (S. aureus); solid arrows5mass transfer between compartments;
dashed arrows5 stimulatory effects; —-|: inhibitory effects. AR, adaptive resistance; CFU, colony forming unit; GRO, growing state;
LZD, linezolid; PER, persisting bacteria; REP, replicating state.
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degradation rate constants of 0.019 h21 for MER and
0.0039 h21 for VAN, respectively, on the initial drug concen-
tration. Yet, degradation alone was not sufficient to explain
the observed regrowth after initial killing for MER and VAN
at concentrations around their MIC values (cf. M1 and
V1 in Figure 2). The adaption process was assumed to
occur on the level of EC50 using an adaption model from




52s3CVAN tð Þ3ARVAN;off IC5 1 (12)
dARon;VAN
dt
5s3CVAN tð Þ3ARVAN;off IC5 0 (13)
EC50;VAN tð Þ5aVAN tð Þ3EC50;VAN;t50 with aVAN tð Þ511bVAN3ARon;VAN tð Þ
(14)
Figure 2 Visual predictive check plots for the final semimechanistic pharmacodynamic model for methicillin-susceptible Staphylococcus
aureus ATCC 29213. Points represent experimental data; the red line indicates median prediction and the gray shaded area represents
the 90% prediction intervals based on 1,000 stochastic simulations for each scenario. Lx/Mx/Vx5multiples/fractions of the minimum
inhibitory concentration of linezolid, meropenem, and vancomycin, respectively. CFU, colony forming unit.




Table 1 Parameter estimates of the final semimechanistic PD model for MSSA ATCC 29213
Parameter [unit] Estimate RSE % [95% CI] Explanation
Parameters of the bacterial life-cycle
CFU0 [log10 CFU/mL] 6.06 0.4 [6.02–6.09] Initial CFUs/mL at beginning of the experiment
CFUmax [log10 CFU/mL] 9.43 0.6 [9.26–9.68] Maximum attainable bacterial growth
klag [h
21] 0.88 16.0 [0.662–2.28] First-order time delay rate constant to attain log-phase
krep [h
21] 1.56 7.2 [1.25–1.90] Transit rate constant from growing to replicating state; rate-
limiting step for growth
kdoub [h
21] 100 FIX [-] Rate constant of doubling; represents actual replication (fixed to
high rate constant as not rate-limiting); MER and VAN
impaired successful replication
kdeath, per [h
21] 0.23 9.3 [0.189–0.307] Basal death rate constant of persistent bacteria
Drug-related parameters
EC50,LZD [mg/L] 0.68 9.1 [0.563–0.802] CLZD leading to half-maximum drug effect of LZD on krep (growth
arrest) and stimulation of kdeath,LZD
HLZD [-] 1.55 7.5 [1.35–1.63] Hill factor LZD (steepness of the concentration-effect
relationship)
kdeath, LZD [h
21] 0.10 7.5 [0.092–0.114] Basal death rate constant of growth-arrested bacteria, induced
by LZD
EC50,MER,t50 [mg/L] 0.022 2.8 [0.0189–0.0262] CMER leading to half-maximum drug effect of MER on kdoub and
kper,MER at t50
HMER [-] 3.23 11.7 [2.27–5.48] Hill factor MER (steepness of the concentration-effect
relationship)
EmaxMER,Eagle,% 32.8 5.9 [26.2–35.6] Percentage by which the effect of MER at higher concentration
decreased from maximum (67.2% impaired doublings
remained)
EC50,MER,Eagle [mg/L] 1.35 8.9 [0.856–1.41] CMER leading to half-maximum paradoxical effect of MER on
kdoub
HMER, Eagle [-] 4 FIX [-] Hill factor MER (steepness of the concentration Eagle-effect
relationship)
bMER [-] 9.53 4.2 [7.61–22.0] Factor that calculates maximum possible adapted EC50 of bacte-
ria by [(11bMER)3 EC50,MER,t50]
sMER [L/(mgh)] 0.47 5.8 [0.154–0.653] Second-order delay rate constant for adaption with respect to
time and CMER
kper,MER [h
21] 0.11 32.6 [0.0545–0.263] Persister development rate for MER during replication
kdeg,MER [h
21] 0.019 FIX [-] First-order degradation rate constant of CMER; drug degradation
determined by HPLC, hence, fixed during estimation
EmaxVAN, % 74.3 1.9 [70.8–78.5] Percentage by which VAN decreased successful doubling at
maximum
EC50,VAN,t50 [mg/L] 0.46 1.8 [0.430–0.482] CVAN leading to half-maximum drug effect of VAN on kdoub and
kper,VAN at t50
HVAN [-] 20 FIX [-] Hill factor VAN (steepness of the concentration-effect relation-
ship); fixed as estimation was not possible and very steep
(on/off) initial concentration-effect relationship was observed in
time-kill curves
EC50,VAN,ARI [mg/L] 0.39 5.0 [0.293–0.515] CVAN leading to half-maximum suppression of adaption of MSSA
to MER
H,VAN,ARI [-] 1.0 FIX [-] Hill factor VAN for suppression of adaption of MSSA to MER
bVAN [-] 3.59 6.7 [2.60–4.81] Factor that calculates maximum possible adapted EC50 of bacte-
ria by [(11bVAN)3 EC50,VAN,t50]
sVAN [L/(mgh)] 0.034 11.2 [0.0197–0.0638] Second-order delay rate constant for adaption with respect to
time and CVAN
kper,VAN [h
21] 0.017 50.9 [0.00722–0.0561] Persister development rate constant for VAN during replication
kdeg,VAN [h
21] 3.9e-03 FIX [-] First-order degradation rate constant of CVAN; drug degradation
determined by HPLC, as an independent variable, was fixed
during estimation
r [log10 CFU/mL] 0.63 - Residual additive variability, no RSE reported as calculated from
final objective function value
CFU, colony forming unit; CI, confidence interval; EC50, half-maximal effective concentration; Emax, maximum effect; HPLC, high-performance liquid chromatog-
raphy; LZD, linezolid; MER, meropenem; MSSA, methicillin-susceptible Staphylococcus aureus; PD, pharmacodynamic; RSE, relative standard error; VAN,
vancomycin.
Relative standard errors (RSE) in % obtained from the variance-covariance matrix, 95% confidence intervals determined by a non-parametric bootstrap analy-
sis (n51198) and short explanation of the model parameters.
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3sMER3CMER tð Þ3ARoff ;MER IC5 0 (16)
EC50;MER tð Þ5aMER tð Þ3EC50;MER;t50 with aMER tð Þ511bMER3ARon;MER tð Þ
The model also comprised a PD interaction on the adap-
tion level (EVAN,ARI; i.e., subinhibitory concentrations of
VAN delayed the adaption of MSSA to MER), which was
highly significant (D-2LL52663.20). This can be seen in
the data when inactive V0.5 is added to M1 that alone
displayed bacterial regrowth, whereas V0.5M1 did not
display any regrowth (Figure 2). Conversely, if a poten-
tial PD interaction on the adaption level between MER
influencing the adaption of MSSA to VAN was evaluated,
the more complex model with both adaption processes
resulted in a worse model fit than the final model and
also the likelihood ratio test favored the final model. This
indicates a monodirectional interaction between VAN and
MER on the adaption level, of which the mechanism
remains to be elucidated in future studies. All PK-PD
model parameters are presented in Table 1. The R code
of the final model is presented in Code S1 in the Supple-
mentary Material.
Model evaluation
The visual predictive check indicated that the final semime-
chanistic PK-PD model well described all experimental data
(Figure 2). The external evaluation focusing on the cross-
strain prediction indicated that the developed PK-PD model
was capable to predict the time-kill curves of a single drug
or dual combinations in clinical MSSA isolates other than
the reference strain ATCC 29213 that was utilized for model
building (Figure 3a). This indicates that the antagonism
between LZD and MER and the additive-to-synergistic inter-
action between VAN and MER is not limited to ATCC
29213, but also present in other (clinical) MSSA strains.
The external evaluation focusing on prediction of combined
effects of other drugs with similar mechanisms of (inter)ac-
tion revealed that the developed semimechanistic PK-PD
model successfully predicted antagonism between VAN, peni-
cillin, and ampicillin as cell wall-active antibiotics and LZD,
erythromycin, and chloramphenicol as protein-synthesis
inhibitors (Figure 3b). The time courses of the predictions of
the external validation are presented in the Supplementary
Figures S2–S4.
Prediction of PK-PD indices and breakpoints
The simulated dose fractionation study displayed for MER
that unbound drug concentrations above the MIC (f%T>MIC)
correlated best with the antibacterial effect at 24 hours
(Figure 4). If the drug concentrations exceeded the MIC
over 50% or 65% of the 24-hour period, a bacteriostatic or
bactericidal effect, respectively, was observed. For LZD, both
f%T>MIC and fAUC/MIC correlated well with the antibacterial
effect and had to exceed 98% of the 24-hour period or 56,
respectively, for a bacteriostatic effect. No bactericidal effect
was attained. For VAN, differentiation between the investi-
gated PK-PD indices was less distinct. For fAUC/MIC, as tra-
ditionally monitored in a clinical setting, 59 or 94 were
associated with a bacteriostatic or bactericidal effect,
respectively.
Figure 3 (a) External evaluation of the semimechanistic pharmacokinetic-pharmacodynamic model to predict time-kill curves of
selected drug combinations of methicillin-susceptible Staphylococcus aureus (S. aureus) isolates MV13391 and MV13488;
(b) observed vs. predicted log10 colony forming unit (CFU)/mL for the external evaluation for the antibiotics vancomycin (VAN) and
linezolid (LZD) against methicillin-resistant S. aureus, penicillin (PEN) and erythromycin (ERY) against S. pneumoniae and ampicillin
(AMP) and chloramphenicol (CHL) against group B streptococci, detailed predicted and observed time-kill curve data is presented in
the Supplementary Material.





The simulated dosing scenarios with the linked population
PK-PD model are illustrated in Figure 5. The clinical trial
simulation of MER of 1,000 mg t.i.d. in the virtual patient
population resulted in unbound Cmax was of 32.3 mgL
(22.2–45.9 mg/L) in median (5th-95th percentile) (22.2–
45.9 mg/L) and unbound Cmin was 0.48 mg/L (0.018–
2.76 mg/L) after the first dose (Figure 5). The predicted
time-course of the antibacterial effect indicated that the
regimen was effective against MSSA and in 88% of the
virtual patients a bactericidal effect was attained at 24
hours.
For LZD, the standard regimen of 600 mg LZD b.i.d.
resulted in unbound Cmax of 11.6 mg/L in median (5th-
95th percentile: 6.7818.2 mg/L) and unbound Cmin of 4.20
mg/L in median (1.677.20 mg/L) after the first dose. This
resulted only in marginal median killing to 5.3 log10 CFU/
mL with a narrow effect spread (90% prediction interval
(PI)55.0–6.3 log10 CFU/mL) after 24 hours, indicating
that, for most virtual patients, the maximum effect was
attained.
VAN 1,000 mg b.i.d. resulted in unbound Cmax of 18.2
mg/L in median (5th-95th percentile: 11.5–37.1 mg/L) and
unbound Cmin of 2.11 mg/L in median (1.14–3.92 mg/L)
after the first dose. The predicted time-kill curves showed
that this regimen was bactericidal in median, and after 24
hours for 84% of the virtual patients the bacterial load was
lower than 3.0 log10 CFU/mL.
The combination of LZD 600 mg b.i.d. with MER
1,000 mg t.i.d. stimulated a bacteriostatic effect to a
median bacterial load of 4.8 log10 CFU/mL after 24
hours (90% PI5 4.6–5.0 log10 CFU/mL), being substan-
tially inferior to the effect of MER 1,000 mg t.i.d. alone
after 24 hours (median5 1.4 log10 CFU/mL; 90%
PI51.2–6.3 log10 CFU/mL), but slightly larger com-
pared to LZD 600 mg b.i.d. alone after 24 hours
(median55.3 log10 CFU/mL; 90% PI5 5.0–6.3 log10
CFU/mL).
Figure 4 Prediction of pharmacokinetic-pharmacodynamic (PK-PD) indices fCmax/MIC (Cmax, peak plasma concentration, MIC, mini-
mum inhibitory concentration), fAUC/MIC (AUC, area under the curve), and %fT>MIC for meropenem (MER), linezolid (LZD), and van-
comycin (VAN) against methicillin-resistant Staphylococcus aureus. Points represent simulated log10 colony forming unit (CFU)/mL at
24 hours using the linked population PK-PD model, dashed horizontal lines at 6 log10 CFU/mL represent inoculum and bacteriostatic
effect, dashed horizontal line at 3 log10 CFU/mL represents bactericidal effect, red lines represent prediction of an inhibitory sigmoidal
maximum effect model fitted to the simulated data, and R25 coefficient of determination.
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The combination of VAN 1,000 mg b.i.d. with MER
1,000 mg t.i.d. resulted in a bactericidal effect at 24 hours,
as observed with both antibiotics individually. However, the
combinatory regimen reduced the observed interindividual
variability of the antibacterial effects observed with the sin-
gle antibiotic regimens (Figure 5) and a bacterial load of
1.3 log10 CFU/mL (90% PI51.1–1.5 log10 CFU/mL) was
attained at 24 hours.
DISCUSSION
The present study compared the commonly used combina-
tion therapies LZD-MER and VAN-MER in a translational
framework exploiting preclinical in vitro studies. By linking
the developed semimechanistic PK-PD model based upon
preclinical information to clinical population PK data of the
three antibiotics, we could translate single and combined
Figure 5 Predicted drug concentration and colony forming unit (CFU)/mL for methicillin-susceptible Staphylococcus aureus against a
monotherapy of linezolid (LZD) 600 mg b.i.d. (red), meropenem (MER) 1,000 mg t.i.d. (yellow), and vancomycin (VAN) 1,000 mg b.i.d.
(blue) or their dual MER-based combination therapies with the same dosing. Median prediction (dotted lines) of unbound drug concentra-
tions (pharmacokinetic (PK); upper panel) and drug effect as log10 CFU/mL over time (pharmacodynamic (PD); lower panel), variability
(shaded area) ranging from the 5th to the 95th percentile (20th, 40th, 60th, 80th, and 90th prediction intervals), dashed horizontal line at 6
log10 CFU/mL represents inoculum and bacteriostatic effect, dashed horizontal line at 3 log10 CFU/mL represents bactericidal effect.




effects of LZD, VAN, and MER into a clinical perspective:
MER and VAN alone displayed considerably rapid bacteri-
cidal activity for most of the virtual patients. The predictions
for LZD alone indicated only a bacteriostatic effect. The com-
bination of MER and VAN displayed an additive interaction
and subinhibitory concentrations of VAN even prevailed the
AR development of MER leading to an overall higher rate of
bactericidal activity compared to each drug alone. The com-
bination of LZD and MER displayed an unfavorable interac-
tion and the bactericidal effect of MER alone was
antagonized to bacteriostasis with only marginal bacterial kill-
ing. In clinical situations when bactericidal activity is deemed
favorable (e.g., infections in neutropenic patients or in treat-
ing endocarditis),31 clinicians should be watchful when apply-
ing the combination MER-LZD and may consider MER-VAN
in these cases.
PK-PD modeling has proven to be a useful tool to com-
prehensively and systematically evaluate combination ther-
apies,32,33 which is difficult to perform in a pure clinical
setting due to resource or ethical constraints. To be able to
capture replication dependent and independent drug
effects, we used a simplified blueprint of the bacterial life
cycle11 for simultaneously modeling of the single and com-
bined effects. The life-cycle model enabled to include the
drug effects motivated by their respective mode of action.
As cell wall-active antibiotics, MER and VAN were assumed
to exert a replication-dependent effect (i.e., perturbation of
successful doubling), whereas LZD, as a protein-synthesis
inhibitor, inhibited the transition into the replicating state.
Thereby, the antagonism between LZD and MER was
already intrinsically implemented as the effect of LZD
growth-arrested the bacterial life-cycle and, thus, precluded
the effect of MER. The combined effects of VAN and MER
were implemented as an inhibitory replication-dependent
effect, reducing the percentage of successful doublings
according to a modified Bliss Independence term.34,35 The
core of this term, (1-EMER)3(1-EVAN), was extended to
account for the observed deviations from conventional Bliss
Independence, including the inferior maximum effect of
VAN compared to MER, the paradoxically reduced “Eagle-
effect”36 at higher concentrations observed for MER, and
the VAN-limited combined effect of combinations of VAN
and MER.
The developed semimechanistic PK-PD model in the pre-
sent study was successfully evaluated with external data
for prediction into other clinical MSSA strains, supporting
the generalizability of our results in MSSA-related infec-
tions. Moreover, the semimechanistic PK-PD model was
capable to predict further antagonistic interactions from a
larger number of published studies indicating that the struc-
tural PK-PD model can be also applied to further drug com-
binations of bacteriostatic and bactericidal drugs. Last, we
also assessed the relation of the semimechanistic PK-PD
model to typically utilized PK-PD indices and breakpoints
that are used in a clinical setting. For LZD, the determined
value of 56 for fAUC/MIC in the present work is fairly close
to the breakpoints in animals (AUC/MIC of 83)37 and
humans (AUC/MIC of 51–85)38 for bloodstream infections if
protein binding is considered. For MER, the determined
value of 52% f%T>MIC was also in good agreement with
the clinical breakpoint for microbiological response of 54%
determined in patients with lower respiratory tract infec-
tions, in which S. aureus was the second-most abundant
pathogen.39 For VAN, the fAUC/MIC breakpoints from the
clinical studies40,41 tended to be fairly higher (125–400)
than the calculated values (59–94) of the present work,
which could originate from the partly impaired tissue distri-
bution of VAN,42 whereas for MER and LZD, unbound
plasma concentrations might be a fair predictor of tissue
concentrations,43–45 if determined under appropriate ana-
lytic conditions.24,46,47 Yet, the overall “correct” prediction of
the PK-PD index indicates that the developed semimechan-
istic PK-PD model might adequately reflect the clinical situ-
ation for the antibiotics LZD, MER, and VAN and, hence,
might support the validity of the drawn conclusions from the
present translational study. For future studies, it might be
valuable to explore the combined drug effects of LZD,
MER, and VAN in scenarios that are longer than 24 hours.
In particular, addition of dynamic time-kill curve data from,
for example, hollow-fiber experiments might be valuable to
provide insight into persistent drug effects, including poten-
tial interactions on these. The present model could aid in
the optimal design of such experiments.
CONCLUSION
The present study compared two common empiric broad-
spectrum antibacterial regimens consisting of LZD-MER
and VAN-MER against MSSA as the highest-abundant
pathogen in many infections. Using preclinical in vitro data
studies combined with clinical population PK data of the
antibiotics, we could evaluate these regimens in a transla-
tional approach with a comprehensively evaluated semime-
chanistic PK-PD model. If bactericidal activity is warranted,
clinicians may favor the combination of VAN-MER over
LZD-MER due to the unfavorable and likely clinically rele-
vant antagonistic interaction between LZD and MER.
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